Prognostic value of HMGN family expression in acute myeloid leukemia.

Abstract

Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1-5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.

• Authors: Wei Cui, Yuna Liu, Yanan Tan, Xingyue Peng, Longzhen Cui, Zhiheng Cheng, Yifeng Dai, Lin Fu, Tiansheng Zeng, Yan Liu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 17 Issue 5 Pg. 541-548 (Feb 2021) ISSN: 1744-8301 [Electronic] England
• PMID: 33467898 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Biomarkers, Tumor
• HMGN Proteins
• HMGN2 Protein
• HMGN5 protein, human
• Trans-Activators

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Biomarkers, Tumor (genetics)
• Female
• Follow-Up Studies
• Gene Expression Profiling
• Gene Expression Regulation, Leukemic
• HMGN Proteins (genetics)
• HMGN2 Protein (genetics)
• Hematopoietic Stem Cell Transplantation (statistics & numerical data)
• Humans
• Kaplan-Meier Estimate
• Leukemia, Myeloid, Acute (diagnosis, genetics, mortality, therapy)
• Male
• Middle Aged
• Prognosis
• Progression-Free Survival
• Trans-Activators (genetics)
• Young Adult